4-Hydroxyphenylpyruvate Dioxygenase-Like Protein Promotes Pancreatic Cancer Cell Progression and Is Associated With Glutamine-Mediated Redox Balance

作者：Xianglai Ye, Xiujuan Wei, Jing Liao, Peipei Chen, Xueyun Li, Yulong Chen, Yue Yang, Qiongya Zhao, Hongwei Sun, Liming Pan, Guorong Chen, Xujun He, Jianxin Lyu, Hezhi Fang · 发表于：Frontiers in Oncology · 年份：2021 · DOI：10.3389/fonc.2020.617190 · 被引用次数：24 · 研究领域：Cancer, Hypoxia, and Metabolism、Epigenetics and DNA Methylation、Pancreatic and Hepatic Oncology Research

Tumor cells develop a series of metabolic reprogramming mechanisms to meet the metabolic needs for tumor progression. As metabolic hubs in cells, mitochondria play a significant role in this process, including energy production, biosynthesis, and redox hemostasis. In this study, we show that 4-hydroxyphenylpyruvate dioxygenase-like protein (HPDL), a previously uncharacterized protein, is positively associated with the development of pancreatic ductal adenocarcinoma (PDAC) and disease prognosis. We found that overexpression of HPDL in PDAC cells promotes tumorigenesis in vitro , whereas knockdown of HPDL inhibits cell proliferation and colony formation. Mechanistically, we found that HPDL is a mitochondrial intermembrane space localized protein that positively regulates mitochondrial bioenergetic processes and adenosine triphosphate (ATP) generation in a glutamine dependent manner. Our results further reveal that HPDL protects cells from oxidative stress by reprogramming the metabolic profile of PDAC cells toward glutamine metabolism. In short, we conclude that HPDL promotes PDAC likely through its effects on glutamine metabolism and redox balance.